1-10 of 10
Yajing Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 661: An oral Cbl-b inhibitor with sustained T cell activation demonstrated robust anti-tumor efficacy along with enhanced infiltration and activation of functional T cells

Feng Zhou, Guimei Yang, Yajing Liu, Liting Xue, Weijie Chen, Zhengtao Li, Xiaowu Liu, Jian Li, Renhong Tang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 661.
https://doi.org/10.1158/1538-7445.AM2024-661
Published: 22 March 2024
View article titled, Abstract 661: An oral Cbl-b inhibitor with sustained T cell activation demonstrated robust anti-tumor efficacy along with enhanced infiltration and activation of functional T cells
Journal Articles

Abstract 7278: Discovery of a novel WRN inhibitor, ZM-3329 that efficiently inhibits MSI-H tumor growth

Feng Zhou, Guimei Yang, Yajing Liu, Liting Xue, Yao Guo, Zhengtao Li, Weikun Wang, Jian Li, Renhong Tang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7278.
https://doi.org/10.1158/1538-7445.AM2024-7278
Published: 22 March 2024
View article titled, Abstract 7278: Discovery of a novel WRN inhibitor, ZM-3329 that efficiently inhibits MSI-H tumor growth
Journal Articles

Abstract 3474: Identification of the selective CBL-b inhibitors which effectively prevent T cells from exhaustion and demonstrate synergistic anti-tumor activity in combination with an anti-PD1 antibody

Feng Zhou, Zhengtao Li, Yajing Liu, Guimei Yang, Wansun Mai, Wenqing Yang, Liting Xue, Ping Chen, Renhong Tang
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3474.
https://doi.org/10.1158/1538-7445.AM2023-3474
Published: 04 April 2023
View article titled, Abstract 3474: Identification of the selective CBL-b inhibitors which effectively prevent T cells from exhaustion and demonstrate synergistic anti-tumor activity in combination with an anti-PD1 antibody
Journal Articles

Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy

Yajing Liu, Wenbin Ji, Andrea Shergalis, Jiaqi Xu, Amy M. Delaney, Andrew Calcaterra, Anupama Pal, Mats Ljungman, Nouri Neamati, Alnawaz Rehemtulla
Journal: Cancer Research
Cancer Res (2019) 79 (11): 2923–2932.
https://doi.org/10.1158/0008-5472.CAN-18-2540
Published: 03 June 2019
View article titled, Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy
Open the PDF for Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy in another window
Includes: Supplementary data
Journal Articles

Abstract 4454: Targeting the gp130 receptor in preclinical models of triple-negative breast cancer

Leonel F. Hernandez-Aya, Yajing Liu, Kelsey Kerr, Shuzo Tamura, Nouri Neamati, Max S. Wicha, Monika L. Burness
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4454.
https://doi.org/10.1158/1538-7445.AM2015-4454
Published: 01 August 2015
View article titled, Abstract 4454: Targeting the gp130 receptor in preclinical models of triple-negative breast cancer
Journal Articles

Abstract 4226: Histone deacetylase inhibitors sensitize cancer stem cells to PARP inhibitors in triple-negative breast cancer

Yajing Liu, Rachel Martin-Trevino, Li Shang, April Davis, Max Wicha, Suling Liu, Monika Burness
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4226.
https://doi.org/10.1158/1538-7445.AM2015-4226
Published: 01 August 2015
View article titled, Abstract 4226: Histone deacetylase inhibitors sensitize cancer stem cells to PARP inhibitors in triple-negative breast cancer
Journal Articles

MicroRNA100 Inhibits Self-Renewal of Breast Cancer Stem–like Cells and Breast Tumor Development

Lu Deng, Li Shang, Shoumin Bai, Ji Chen, Xueyan He, Rachel Martin-Trevino, Shanshan Chen, Xiao-yan Li, Xiaojie Meng, Bin Yu, Xiaolin Wang, Yajing Liu, Sean P. McDermott, Alexa E. Ariazi, Christophe Ginestier, Ingrid Ibarra, Jia Ke, Tahra Luther, Shawn G. Clouthier, Liang Xu, Ge Shan, Erwei Song, Herui Yao, Gregory J. Hannon, Stephen J. Weiss, Max S. Wicha, Suling Liu
Journal: Cancer Research
Series: Author Choice
Cancer Res (2014) 74 (22): 6648–6660.
https://doi.org/10.1158/0008-5472.CAN-13-3710
Published: 13 November 2014
View article titled, MicroRNA100 Inhibits Self-Renewal of Breast Cancer Stem–like Cells and Breast Tumor Development
Open the PDF for MicroRNA100 Inhibits Self-Renewal of Breast Cancer Stem–like Cells and Breast Tumor Development in another window
Includes: Supplementary data
Journal Articles

Abstract 3893: Interleukin 6 and interleukin 8 inhibitors, when used in combination with docetaxel, inhibit tumor progression in mouse model of triple-negative breast cancer

Yajing Liu, Leonel Hernandez-Aya, April Davis, Max Wicha, Monika Burness
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 3893.
https://doi.org/10.1158/1538-7445.AM2014-3893
Published: 01 October 2014
View article titled, Abstract 3893: Interleukin 6 and interleukin 8 inhibitors, when used in combination with docetaxel, inhibit tumor progression in mouse model of triple-negative breast cancer
Journal Articles

Abstract 218: MEOX-1 as a novel cancer stem cell target for treatment of trastuzumab-resistant Her2+ breast cancers

Lichao Sun, Joseph P. Burnett, Mari Gasparyan, Hasan Korkaya, Hui Jiang, Yajing Liu, Jamie Connarn, Max Wicha, Duxin Sun
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 218.
https://doi.org/10.1158/1538-7445.AM2014-218
Published: 01 October 2014
View article titled, Abstract 218: MEOX-1 as a novel cancer stem cell target for treatment of trastuzumab-resistant Her2+ breast cancers
Journal Articles

Abstract 3720: Rad51 is involved in PARP inhibitor resistance in triple-negative breast cancer stem cells (TNBCSCs).

Yajing Liu, Rachel Martin, Shoumin Bai, Max Wicha, Suling Liu
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3720.
https://doi.org/10.1158/1538-7445.AM2013-3720
Published: 15 April 2013
View article titled, Abstract 3720: Rad51 is involved in PARP inhibitor resistance in triple-negative breast cancer stem cells (TNBCSCs).